2020 – The American Factor V Leiden Association was formed in Tampa, FL to create more awareness of the disorder, provide an educational resource library, help establish comprehensive testing guidelines, and encourage more scientific research.
2018 – A consumer experience study showed that a majority of participants felt they benefited from knowing that they carried the Factor V Leiden gene mutation after getting their 23andMe test results. Most felt they benefited in becoming aware and felt they now had an increased risk perception of developing a venous thrombosis (VTE). Most of the participants shared the test results with family and/or their health care provider and many took action to reduce their risk after finding out.
2015 – Venous thromboembolism becomes the 3rd leading cause of cardiovascular death (behind myocardial infarction and stroke) and the leading cause of preventable hospital deaths.
2011 – Created in 1953 in Oxford, the thrombin generation test (TGT) was updated. The TGT is a functional test exploring coagulation in its entirety, thus constituting a modern exploration path of hemostasis.
2008 – A new class of anticoagulant drugs are introduced on the market alongside heparins and vitamin K antagonists called direct oral anticoagulants or DOACs.
2002 – Women’s Health Initiative (WHI) results in 2002 found that post-menopausal women taking combination (estrogen and progestin) hormone therapy for menopause symptoms had an increased risk for breast cancer, heart disease, stroke, blood clots, and urinary incontinence.
2001 – The World Health Organization (WHO) recognizes the association between thrombosis and air travel. The likelihood of developing deep vein thrombosis doubles after a flight of about four hours in patients with an increased risk.
1994 – Dr. Rogier Bertina and his team in Leiden, Netherlands discovered that the inherited resistance to activated protein C was associated with a missense mutation in the gene encoding coagulation factor v, which dramatically slowed the cleavage of the activated form of this cofactor by activated protein C. The mutation, called Factor V Leiden, leads to a gain of function of activated factor V, which in turn causes a hypercoagulable state.
1993 – Dr. Björn Dahlbäck discovered and proposed that activated protein C (APC) resistance is an inherited risk factor for venous thrombosis at Lund University in Sweden.
1991 – In 1991, the National Heart, Lung, and Blood Institute, part of National Institutes of Health (NIH), launched the Women’s Health Initiative (WHI) to understand better how cardiovascular disease, breast cancer, colorectal cancer, and osteoporosis affect post-menopausal women and to reduce the number of women who develop and die from these diseases. More than 160,000 post-menopausal women ages 50 to 79 participated in the 15-year study, making it one of the largest prevention studies involving women in the United States.
1983 – Philip Majerus proposes the first anticoagulant function for factor V, yet ultimately it was not widely accepted by the broader scientific community.